Reply to Chughtai et al

To the Editor—We thank Dr Chughtai et al for providing feedback on our article entitled “Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012–2013 Season in the United States.” They point out three main issues with our analysis: (1) exclusion of hospitalized cases who were not treated with antivirals, (2) exclusion of hospitalized cases who were institutionalized in long-term care facilities, and (3) death in the intensive care unit (ICU) as a nonindependent competing risk.

We have carefully reviewed their comments and suggestions, reanalyzed the data, and prepared our responses. We will address the three issues separately:

1. Exclusion of hospitalized cases who were not treated with antivirals.

As mentioned in the article [1], we excluded cases who were not treated with antivirals for two main reasons: (1) most hospitalized cases received antiviral treatment, thus limiting our ability to look at those who were not treated as a separate group; and (2) there were substantial differences between characteristics of treated cases and those untreated. By restricting the analysis to those treated, we avoided selection bias, as we did not have a way to ascertain why some patients were treated while others were not (decision was made at the discretion of the clinician providing care). We acknowledged in our article that antiviral treatment could indeed dilute the effect of vaccination, explaining, perhaps, why we found very modest effects from influenza vaccination. We agree that analyzing the data of untreated patients may be helpful in understanding the effect of influenza vaccination on disease severity. Therefore, we analyzed the data for those untreated without propensity score matching and found no effect in most categories (Table 1). However, in the 50–64-year age group, vaccination did have significantly beneficial effects on severe disease (odds ratio, 0.4) and length of stay (relative hazard of discharge, 1.23). Unfortunately, our sample size was too small to further investigate with propensity score matching. We plan to further explore the effect of influenza vaccination on disease severity among treated and untreated cases using different seasons (with varying matches between circulating influenza viruses and vaccine-selected strains and age groups).

2. Exclusion of hospitalized cases who were institutionalized in long-term care.

For our current study, we aimed to present results regarding the effect of influenza vaccination in disease severity in adults ≥50 years living in the community. Thus, we excluded hospitalized cases with laboratory-confirmed influenza who came from institutionalized long-term care facilities because this is a different population that should be studied separately, as they present significant differences compared to people living in the community [2, 3].

Table 1. Influenza Vaccination and Severity of Influenza Disease Analysis for Cases Untreated With Antivirals by Age Category, Before Propensity Score Matching (n = 966)\(^a\)

<table>
<thead>
<tr>
<th>Clinical Outcomes</th>
<th>50–64 y (n = 328)</th>
<th>65–74 y (n = 232)</th>
<th>≥75 y (n = 406)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe disease(^b) (OR)</td>
<td>0.4 (0.17; 0.98)</td>
<td>0.9 (0.75; 1.32)</td>
<td>0.76 (0.57; 1.04)</td>
</tr>
<tr>
<td>Diagnosis of pneumonia(^c) (OR)</td>
<td>0.83 (0.64; 1.07)</td>
<td>0.91 (0.75; 1.10)</td>
<td>0.85 (0.63; 1.13)</td>
</tr>
<tr>
<td>Length of hospital stay (RH)(^d)</td>
<td>1.23 (1.01; 1.49)</td>
<td>0.95 (0.74; 1.20)</td>
<td>1.20 (1.00; 1.45)</td>
</tr>
</tbody>
</table>

Data excluded: untreated, FluA&B, FluA/B.

Analysis for ICU length of stay was not performed due to small numbers (36, 27, and 37, observations in age groups 50–64, 65–74, and ≥75 years, respectively).

Abbreviations: BMI, body mass index; CI, confidence interval; ICU, intensive care unit; OR, odds ratio; RH, relative hazard.

\(^a\) Adjusted for sex, race, BMI, medical condition (asthma, chronic lung disease, cardiovascular disease, chronic metabolic disease, neurologic disease, immunosuppression, renal disease), alcohol abuse, smoking, and influenza virus type.

\(^b\) Admitted to ICU or deceased.

\(^c\) Among those who had a chest X-ray taken within 3 days of admission (n = 932).

\(^d\) RH represents hospital discharge accounting for death as a nonindependent competing risk.
3. Death in the ICU as a nonindependent competing risk. Finally, we reanalyzed the data using death as a nonindependent competing risk (see Table 2) and found that the probability of being discharged earlier from the ICU accounting for death was 1.6 times higher (95% confidence interval, 1.04–2.46) among vaccinated cases aged 65–74 years compared to those who were unvaccinated, after propensity score matching. The results of this analysis were similar to our previous results; therefore, we reaffirm that our findings show a modest effect of influenza vaccination on disease severity for the influenza season 2012–2013. Analysis of data from seasons with a better match between vaccine strains and circulating viruses and, thus, better vaccine effectiveness against influenza infection are needed.

In addition to the three issues mentioned above, Chughtai et al suggested presenting hospitalization rates by vaccination status among treated and untreated groups. However, even though FluSurv-NET is a population-based surveillance system, we do not have denominator information on influenza vaccination coverage by treatment.

**Notes**

*Disclaimer.* The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC). The content of this article has not been previously presented.

*Financial support.* This work was supported in part by Cooperative Agreement number CDC-RFA-CK12-1202 and 5U38HM000414 from the CDC. The Influenza Hospitalization Surveillance Network (FluSurv-NET) is a collaboration of state health departments, academic institutions, and local partners, and is funded by the CDC.

*Potential conflict of interest.* Both authors: No reported conflicts.

Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**Carmen S. Arriola**<sup>1,2</sup> and **Sandra S. Chaves**<sup>2</sup>

<sup>1</sup>Epidemic Intelligence Service Program, and <sup>2</sup>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia

**References**


Received 8 July 2015; accepted 8 July 2015; electronically published 14 July 2015.

Correspondence: Carmen S. Arriola, DVM, PhD, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS A-32, Atlanta, GA 30329 (wus3@cdc.gov).

The Journal of Infectious Diseases® 2015;212:1684–5

Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US. DOI: 10.1093/infdis/jiv385

CORRESPONDENCE • JID 2015:212 (15 November) • 1685